Published in Oncotarget on January 20, 2015
Curcumin suppresses cell growth and invasion and induces apoptosis by down-regulation of Skp2 pathway in glioma cells. Oncotarget (2015) 0.91
JARID1B promotes metastasis and epithelial-mesenchymal transition via PTEN/AKT signaling in hepatocellular carcinoma cells. Oncotarget (2015) 0.87
miR-19b attenuates H2O2-induced apoptosis in rat H9C2 cardiomyocytes via targeting PTEN. Oncotarget (2016) 0.84
Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer. EBioMedicine (2016) 0.79
Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. Oncotarget (2015) 0.79
Roles of ubiquitination and SUMOylation on prostate cancer: mechanisms and clinical implications. Int J Mol Sci (2015) 0.79
The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2. Cell Cycle (2015) 0.79
Histone demethylase lysine demethylase 5B in development and cancer. Oncotarget (2016) 0.79
Rottlerin exerts its anti-tumor activity through inhibition of Skp2 in breast cancer cells. Oncotarget (2016) 0.77
Curcumin inhibits cell growth and invasion and induces apoptosis through down-regulation of Skp2 in pancreatic cancer cells. Am J Cancer Res (2016) 0.76
Matrine derivative YF-18 inhibits lung cancer cell proliferation and migration through down-regulating Skp2. Oncotarget (2016) 0.75
SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer. Oncogene (2016) 0.75
MMP7 interacts with ARF in nucleus to potentiate tumor microenvironments for prostate cancer progression in vivo. Oncotarget (2016) 0.75
MYC Modulation around the CDK2/p27/SKP2 Axis. Genes (Basel) (2017) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Cancer genome landscapes. Science (2013) 25.33
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol (1999) 9.92
Global histone modification patterns predict risk of prostate cancer recurrence. Nature (2005) 7.03
Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer (2006) 6.76
Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer (2010) 6.27
Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer (2008) 6.10
Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta (2004) 6.03
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol (1999) 5.40
Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science (2010) 4.03
The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell (2003) 3.87
Skp2 regulates Myc protein stability and activity. Mol Cell (2003) 3.85
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell (2007) 3.68
The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol (2008) 3.31
Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell (2004) 3.27
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A (2001) 2.98
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol (2009) 2.91
Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) (2012) 2.59
Identification, analysis, and prediction of protein ubiquitination sites. Proteins (2010) 2.53
JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A (2007) 2.45
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell (2012) 2.30
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging (2003) 2.17
The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell (2013) 2.11
Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol (2010) 1.93
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res (2002) 1.89
Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev (2007) 1.71
Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog (2012) 1.60
Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One (2009) 1.54
Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res (2011) 1.47
Characterization and prediction of protein nucleolar localization sequences. Nucleic Acids Res (2010) 1.40
Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal (2009) 1.39
Histone modifying enzymes and cancer: going beyond histones. J Cell Biochem (2005) 1.38
Targeting histone modifications--epigenetics in cancer. Curr Opin Cell Biol (2013) 1.36
H3K4 demethylation by Jarid1a and Jarid1b contributes to retinoblastoma-mediated gene silencing during cellular senescence. Proc Natl Acad Sci U S A (2012) 1.28
Glutamine methylation in histone H2A is an RNA-polymerase-I-dedicated modification. Nature (2013) 1.27
Skp2: a novel potential therapeutic target for prostate cancer. Biochim Biophys Acta (2011) 1.21
Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet (2005) 1.18
Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci U S A (2009) 1.17
Global levels of histone modifications predict prostate cancer recurrence. Prostate (2010) 1.11
Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget (2013) 1.05
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev (2010) 1.05
Depletion of JARID1B induces cellular senescence in human colorectal cancer. Int J Oncol (2013) 0.96
Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10. Biochem Biophys Res Commun (2010) 0.96
EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer. Oncotarget (2014) 0.94
ARF represses androgen receptor transactivation in prostate cancer. Mol Endocrinol (2013) 0.92
The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. Oncotarget (2014) 0.90
TGF-beta uses the E3-ligase TRAF6 to turn on the kinase TAK1 to kill prostate cancer cells. Future Oncol (2009) 0.90
A novel PF/PN motif inhibits nuclear localization and DNA binding activity of the ESX1 homeoprotein. Mol Cell Biol (2000) 0.89
K63-linked ubiquitination in kinase activation and cancer. Front Oncol (2012) 0.87
Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer. Prostate (2013) 0.87
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential. Tumour Biol (2013) 0.87
SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase. Epigenetics (2013) 0.82
mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide. Nature (2016) 1.46
ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK-RSK pathway. Nucleic Acids Res (2014) 0.81
p27 modulates tropism of mesenchymal stem cells toward brain tumors. Exp Ther Med (2010) 0.75